Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

Inclusion Criteria: * Male or female subjects 18 to 65 years of age * EASI score ≤ 21 at baseline * Diagnosis of mild-to-moderate (grade 2 or 3) AD according to the ISGA scale at Baseline * BSA affected by AD: 5% to 20% at start of treatment * Willing and able to apply study treatments as directed, comply with study instructions, and commit to attending all visits * Willing and able to provide informed consent * Use of adequate birth control, if of reproductive potential and sexually active Exclusion Criteria: * Widespread AD requiring systemic therapy * Use of any of the following treatments within the specified time periods prior to Day 1 * Topical medications (topical antibiotics, topical corticosteroids, topical antifungals, topical antihistamines, topical retinoids, topical calcipotriene, tacrolimus, pimecrolimus, or other topical drug products for treatment of AD) or bleach bath within 2 weeks prior to Day 1 * Systemic agents (cyclosporine, systemic corticosteroids \[oral and injectable; intranasal and inhaled corticosteroids are allowed if use is kept constant during the study\], systemic antibiotics, immunomodulators or immunosuppressive therapies, interferon, cytotoxic drugs \[e.g., methotrexate, cyclophosphamide, azathioprine\], oral retinoids, systemic antifungals, tacrolimus) for the treatment of AD within 4 weeks prior to Day 1 * Ultraviolet (UV) therapy or use of a tanning booth/parlor within 6 weeks prior to Day 1 * Biologic therapies within 12 weeks (or 5 half-lives) prior to Day 1 * Antihistamines within 5 days prior to Day 1 \[stable regimens (consistent use ≥ 14 days before Day 1) of oral H1 antihistamines for non-AD lesion treatment will be allowed\] * Active or potentially recurrent dermatologic condition other than AD that may confound evaluation * Congenital ichthyosis (note that subjects with ichthyosis vulgaris are permitted) * Known allergy to any ingredients of the investigational product formulation * Significant confounding conditions as assessed by Investigator * Any condition that could interfere with any evaluation in the study * Pregnancy or breast feeding * Any reason which, in the opinion of the Investigator, interferes with the ability of the subject to participate in or complete the trial